NCT02435147View on ClinicalTrials.gov

Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index

CompletedOBSERVATIONAL

Enrollment

86

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions

OsteoporosisBone Fracture

Interventions

DRUG

denosumab

Patients will receive denosumab 60 mg subcutaneously every six months as part of their standard osteoporosis treatment.

Trial Locations (1)

55104

HealthEast Care System, Saint Paul

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Amgen

INDUSTRY

lead

HealthEast Care System

OTHER